MELANOMA

This early-phase trial tests a custom-made RNA vaccine designed to help the immune system recognize and attack tumors in people with advanced melanoma or soft tissue sarcoma whose cancer has worsened despite standard immunotherapy. Up to 18 adults will receive three doses of the …

This study tests an experimental drug called AZD6750, designed to help the immune system fight cancer. It is for adults with advanced solid tumors (like melanoma, lung, or breast cancer) that have spread. The trial will first find the safest dose, then test if it works alone or w…

This study tests a new treatment called GC101 TIL for people with advanced melanoma that has not responded to other therapies. The treatment uses a patient's own immune cells, grown in a lab, to fight the cancer. About 98 participants will be randomly assigned to receive either t…

This trial tests a personalized cancer vaccine made from tumor cells grown in a lab. The cells are modified to boost the immune system, then killed and injected into the patient. The goal is to help people with metastatic melanoma, breast, ovarian, colorectal, gastric, lung, or k…

This early-phase study tests a new drug, BI 3810944, in 69 adults with advanced solid tumors or melanoma who have run out of standard options. The goal is to find a safe dose and see if the drug can shrink tumors. Participants receive the drug intravenously, usually every three w…

This study tests an experimental drug called N17350 for people with advanced solid tumors that have not responded to standard treatments. The drug is injected directly into tumor lesions every two weeks for up to 12 weeks. Researchers aim to find the safest and most effective dos…

This study tests a new treatment for people with certain cancers (pancreatic, kidney, breast, melanoma, or ovarian) that have a protein called CD70. Doctors take a sample of your blood, remove white blood cells, modify them in the lab to recognize and attack CD70, and then give t…

This study tests an experimental drug called TRK-950, alone or with another drug (nivolumab), in people with advanced solid tumors or melanoma that have not responded to standard treatments. The goal is to check safety, find the right dose, and see if the drug can shrink tumors. …

This early-stage trial tests a treatment where a child's own immune cells are collected, modified to better attack cancer, and given back as a one-time infusion. It is for children and young adults up to age 21 with solid tumors that have come back or not responded to standard th…

This early-stage study tests two drugs, ulixertinib and palbociclib, together in people with advanced solid tumors, including pancreatic cancer and certain melanomas. The main goal is to find the safest dose and check for side effects. About 45 adults whose cancer has not respond…

This study tests an experimental oral drug called Alintegimod combined with standard immunotherapies (ipilimumab and nivolumab) in people with advanced solid tumors like melanoma, lung, kidney, or liver cancer who have already tried other treatments. The goal is to see if the com…

This study tests whether adding the arthritis drug sarilumab to a three-drug immunotherapy cocktail can make treatment safer and more effective for people with advanced melanoma that cannot be removed by surgery. About 105 participants will receive the combination and be monitore…

This early-stage study tests a new treatment called MQ710, made from a modified virus, for people with advanced solid tumors that have not responded to standard therapies. The treatment is injected directly into tumors, either alone or with the immunotherapy drug pembrolizumab. T…

This study tests a new drug called HLX17 to see if it works like the approved cancer drug Keytruda. It is for people who have had surgery for lung cancer, melanoma, or kidney cancer. The study will compare how the drugs move through the body, their safety, and how well they work.…

This study tests a genetically modified herpes virus (RP1) injected directly into melanoma tumors. The goal is to see if it can kill cancer cells and train the immune system to attack the cancer, reducing the chance it spreads to nearby lymph nodes. About 25 adults with thick or …

This study tests a new way to treat advanced melanoma by boosting a patient's own immune cells. Doctors remove a piece of the tumor, grow special immune cells (TIL) that are enhanced with CD40L, and then give them back after a short chemotherapy. The goal is to shrink or control …

This early-stage study tests an oral probiotic (R-5780) taken alongside a standard immunotherapy drug (PD-1 inhibitor) in adults with advanced solid tumors like melanoma. The main goal is to see if the combination is safe and tolerable. About 33 participants will be enrolled to a…

This study tests whether adding the drug pembrolizumab to a treatment that uses a patient's own immune cells (called TIL therapy) can shrink tumors in people with advanced melanoma. About 170 adults aged 18 to 72 with skin melanoma that has spread will receive chemotherapy, then …

This study tests a new treatment for people with advanced melanoma that has come back or not responded to standard therapy. The treatment uses specially engineered immune cells (CAR-T cells) that target two proteins, NG2 and DLL3, found on melanoma cells. The goal is to see if th…

This study tests pembrolizumab, an immunotherapy that helps the immune system fight cancer, in children aged 6 months to 18 years with advanced melanoma, solid tumors, or lymphoma that has spread, returned, or not responded to treatment. The goal is to see if the drug can shrink …

This study is testing whether combining an immunotherapy drug (atezolizumab), an immune-boosting agent (BDB001), and targeted radiation can help control advanced solid tumors. It includes people with pancreatic cancer, lung cancer, melanoma, bladder cancer, triple-negative breast…

This study tests a new drug called GI-101, either alone or with pembrolizumab or lenvatinib, in people with advanced solid tumors (cancers that have spread). The goal is to see if it is safe and works against the cancer. About 317 adults with certain cancers like lung, kidney, or…

This study tests an experimental pill called IPN01194 in adults with advanced solid tumors (cancers that have spread). The goal is to find the right dose and see if it is safe and can shrink tumors. About 220 people with specific genetic mutations will take the drug by mouth. Thi…

This study looks at how well the drug T-DXd works in adults with advanced HER2-positive solid tumors that have spread and are not responding to other treatments. About 100 people will be followed to see if their tumors shrink and how long that lasts. The goal is to provide a trea…

This early-stage study tests an experimental drug, REGN10597, alone or with another drug (cemiplimab) in people with advanced solid tumors like melanoma and kidney cancer. The main goals are to check safety, find the right dose, and see if the drugs shrink tumors. About 240 parti…

This early-stage study tests a new drug, PF-08046054/SGN-PDL1V, in people with advanced solid tumors that have spread or can't be removed. The drug is given alone or with pembrolizumab to see if it's safe and what side effects occur. About 714 participants with cancers like lung,…

This study tests an experimental treatment called OBX-115 for people with advanced melanoma or non-small cell lung cancer that has spread or come back. The treatment uses a patient's own immune cells (tumor-infiltrating lymphocytes) that are modified to produce a protein (IL15) t…

This study tests a new way to deliver radiation therapy for people with lung cancer, melanoma, or kidney cancer that has started to grow in a few new spots while on other treatments. The approach uses a PET scan to find the most active parts of the tumor and deliver a higher radi…

This study tests a new drug, BMS-986340, alone or with other cancer treatments in people with advanced solid tumors that have not responded to standard therapy. The main goal is to find safe doses and check for side effects. About 949 adults with various cancers like lung, breast…

This study tests a combination of two experimental drugs, HX009 and IN10018, with or without standard chemotherapy, in people with advanced solid tumors like bile duct cancer and melanoma that have not responded to prior treatments. The goal is to find the best dose and see if th…

This early-phase study tests a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors (like melanoma, lung, or colon cancer) that have a specific BRAF gene change and have stopped responding to standard treatments. The drug is given alone or combined w…

This study is for people with advanced solid tumors like melanoma, lung cancer, or liver cancer. It tests whether adding metformin or rosiglitazone (drugs that change how cells use energy) to standard immunotherapy (anti-PD-1) can improve treatment response. Participants will hav…

This study tests whether adding a low-dose chemotherapy drug (cyclophosphamide) to an immunotherapy (pembrolizumab) can shrink tumors in people with advanced melanoma that no longer responds to standard immunotherapy. About 14 adults with stage III or IV melanoma will receive the…

This study tests a drug called entrectinib, already approved for certain lung and solid tumors, in people with rare cancers that have a specific genetic change called ROS1 fusion. About 30 adults, teens, and children with these rare cancers will receive the drug. Researchers will…

This study tests whether giving immunotherapy before and after surgery helps people with advanced melanoma (stage III or IV). About 90 participants will receive treatment based on their tumor's biomarkers. The goal is to see if this approach leads to a major or complete response …

This study tests whether adding hydroxychloroquine (a malaria drug) to standard immunotherapy (nivolumab with or without ipilimumab) can safely improve treatment for advanced melanoma that has spread. About 94 adults with stage III or IV melanoma will take part. The goal is to fi…

This program provides ulixertinib, an experimental drug, to adults with advanced solid tumors that have specific genetic changes (MAPK pathway mutations) and who have run out of standard treatments. The goal is to control the cancer, not cure it. Participants may take ulixertinib…

This study looks at whether adding a precise type of radiation (stereotactic radiosurgery) to standard drug therapy can better control brain tumors in people with melanoma or non-small cell lung cancer that has spread to the brain. About 180 participants with newly diagnosed, unt…

This early-phase study tests a new treatment called IDOV-Immune, a virus designed to infect and kill cancer cells while boosting the immune system. It is for adults with advanced solid tumors (like colorectal, pancreatic, or lung cancer) that have not responded to standard treatm…

This study is testing an experimental drug called NUC-7738, given alone or with another drug (pembrolizumab), in people with advanced solid tumors or lymphoma that have not responded to other treatments. The goal is to find the safest dose and see if it can shrink tumors or slow …

This study is testing a new drug called DXC014 in people with advanced solid tumors, including small cell lung cancer, melanoma, and prostate cancer. The main goals are to check the drug's safety, find the best dose, and see if it can help shrink tumors. About 150 participants wi…

This study tests whether adding a fecal microbiota transplant called LND101 to standard immunotherapy can help keep advanced melanoma from growing or spreading. About 128 people with stage IV or unresectable melanoma will receive either immunotherapy alone or with LND101. The goa…

This early-phase trial tests a new treatment for people with advanced solid tumors (sarcoma, lung cancer, or melanoma) that have not responded to first-line therapy. The treatment involves taking a patient's own immune cells, modifying them in the lab to better recognize and atta…

This study tests an experimental drug called patritumab deruxtecan in people with advanced solid tumors that have spread or cannot be removed. The trial includes 740 participants with 13 different cancer types, such as lung, breast, and prostate cancer. The goal is to see if the …

This study is for people with stage III melanoma that has spread to just one lymph node. Doctors want to see if removing only that cancerous node can prevent the cancer from coming back in the same area, compared to removing more nodes. The trial will also track side effects like…

This study tests a new two-drug combination (fianlimab and cemiplimab) against an already approved combination (relatlimab and nivolumab, sold as Opdualag) in people with advanced melanoma that cannot be removed by surgery or has spread. About 560 adults who have not had prior tr…

This study tests a combination of three immune-based treatments—CAR T cells, cytotoxic T lymphocytes (CTLs), and dendritic cell (DC) vaccines—in people with advanced melanoma that has not responded to standard therapy. The goal is to see if this approach is safe and can shrink tu…

This study looks at whether adding radiation therapy to standard immunotherapy can lower the chance of melanoma coming back in nearby lymph nodes. It involves 168 adults with high-risk melanoma that has spread to a sentinel lymph node but not farther. Participants will receive ra…

This study tests whether adding low-dose radiation to the liver can help immunotherapy work better for people with melanoma or non-small cell lung cancer that has spread to the liver. About 21 participants will receive standard immunotherapy plus low-dose liver radiation. The goa…

This study tests an experimental oral drug called NEO212 in people with certain brain tumors (astrocytoma, glioblastoma) or cancers that have spread to the brain. The goal is to find the safest dose and see if it helps control the disease. About 134 adults will take part across t…

This early-stage trial tests a new drug called BI-1808, alone or with another drug (pembrolizumab), in people with advanced cancers (like ovarian cancer, melanoma, or T-cell lymphoma) that have not responded to standard treatments. The main goals are to check safety, find the bes…

This early-stage trial tests a treatment made from your own immune cells (called tumor-infiltrating lymphocytes, or TILs) for people with advanced uveal melanoma (an eye cancer) or certain sarcomas (soft tissue cancers). About 30 participants will have their tumor removed, immune…

This study is testing a new drug, enzelkitug, for people with advanced solid tumors that have spread or cannot be removed by surgery. The trial includes many cancer types like lung, head and neck, melanoma, breast, and others. The main goal is to check the drug's safety and find …

This early-stage trial tests a new drug called GV20-0251 in people with advanced solid tumors that no longer respond to standard treatments. The main goal is to check the drug's safety. About 10 adults with cancers like liver, lung, or skin cancer will take part. This is not a cu…

This study offers continued access to dabrafenib and/or trametinib for up to 100 patients with melanoma, lung cancer, or other solid tumors who were already benefiting from these drugs in a prior Novartis or GSK trial. The main goal is to monitor long-term safety and side effects…

This study tests a combination of two drugs, enfortumab vedotin and pembrolizumab, in people with advanced melanoma that has worsened after standard treatments. The goal is to see if this combo can shrink tumors. About 60 adults with unresectable stage III or IV melanoma will tak…

This study is testing a type of internal radiation called high-dose-rate brachytherapy for people with liver tumors that cannot be surgically removed. The treatment uses a tiny radioactive source placed directly into the tumor to kill cancer cells while sparing nearby healthy tis…

This study is testing an experimental drug called MGC026 in about 250 adults with advanced solid tumors that have not responded to other treatments. The main goals are to check the drug's safety and find the right dose. Participants receive the drug by IV and are closely monitore…

This study is testing whether a combination of two drugs, axitinib and ipilimumab, can shrink tumors in people with advanced melanoma that has not responded to standard immunotherapy. About 25 adults with advanced or spreading melanoma will receive the treatment. The goal is to s…

This study tests two drugs, vemurafenib and cobimetinib, already approved for melanoma, in adults with other rare cancers that have a specific BRAF V600 gene change. About 30 people will take the drugs to see if their tumors shrink or stop growing. The goal is to find new uses fo…

This study tests whether combining a personalized cell therapy (lifileucel) with an immunotherapy drug (pembrolizumab) works better than the drug alone for people with advanced melanoma that cannot be removed by surgery or has spread. About 670 adults with untreated melanoma will…

This trial tests a drug called atezolizumab, already approved for some cancers, in people with rare cancers that have high numbers of genetic mutations or specific DNA repair problems. About 30 adults and children with these rare tumor types will receive the drug. The main goal i…

This early-stage study tests an experimental oral drug, NST-628, in adults with advanced solid tumors that have specific genetic changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it shrinks tumors. About 230 participants w…

This study tests a treatment called electrochemotherapy for people with tumors in organs like the liver or pancreas that cannot be removed with surgery. The treatment uses short electric pulses to help chemotherapy drugs enter cancer cells more effectively. The goal is to see if …

This study tests whether a combination of three immunotherapy drugs (relatlimab, nivolumab, and ipilimumab) can shrink or stabilize melanoma tumors that have spread to the brain. About 60 adults with melanoma brain metastases will receive the drugs intravenously. The main goal is…

This study tests whether adding a drug called tarlatamab to standard radiation therapy is safe and effective for cancers that have a protein called DLL3, such as certain lung cancers, melanomas, and bladder cancers. About 30 adults with advanced or returning cancers will receive …

This study tests an experimental drug called GV20-0251 in adults with advanced solid tumors (like lung, head and neck, or colon cancer) that have stopped responding to standard therapies. The goal is to see if the drug can shrink tumors or slow their growth. About 350 participant…

This study tests whether giving two doses of immunotherapy drugs (ipilimumab and nivolumab) before surgery can help shrink tumors in people with melanoma that has come back after previous treatment. About 25 adults with advanced but removable melanoma will receive the drugs, then…

This study tests a new treatment called T3011, given as a shot directly into tumors, for people with advanced or metastatic solid tumors (like melanoma or lung cancer). It is for adults whose cancer has worsened after standard treatments. The goal is to see if T3011 is safe and c…

This study tests a new experimental drug (PF-07799544) combined with another drug (PF-07799933) in adults with advanced solid tumors that have a specific gene change called BRAF V600. The goal is to see if the combination is safe and can shrink or control the cancer. Participants…

This study tests a drug called tegavivint in children, teens, and young adults (ages 1 to 30) whose solid tumors have returned or are not responding to standard treatments. The drug works by blocking a key signal that tells cancer cells to grow. The trial aims to find the safest …

This early-stage study tests an experimental drug called VSV-02 in 6 adults with advanced solid tumors (like melanoma, breast, or lung cancer) who have run out of standard options. The drug is given both into a vein and directly into the tumor to see if it can shrink or control t…

This study tests whether adding a prebiotic-rich diet to standard immunotherapy (ipilimumab and nivolumab) before surgery helps melanoma patients respond better. About 35 adults with stage III or IV melanoma will follow the diet and take the drugs. The goal is to see if the diet …

This study is testing a new radioactive tracer that targets a protein called LRRC15, found on many cancers like pancreatic, breast, lung, and brain tumors. The tracer is used with PET scans to see if it can better detect and stage these cancers compared to standard scans. The stu…

This study looks at whether a special ultrasound using a contrast agent (Sonazoid) can find the first lymph node where cancer might spread, called the sentinel node, as accurately as the current radioactive method. About 91 adults with melanoma, breast cancer, or head & neck canc…

This study is testing a new platform that uses advanced testing to better understand different types of cancer, including leukemia, myeloma, and solid tumors. The goal is to see if this platform can change the recommended treatment for patients, making it more personalized. About…

This study tests if a surgery called lymphovenous bypass, done before lymph node removal, can prevent lymphedema (arm swelling) in people with breast cancer or melanoma. About 252 participants will be followed to see if the bypass reduces the chance of swelling compared to standa…

This study compares a new radiation technique called lattice radiation therapy (LRT) to standard stereotactic body radiation therapy (SBRT) for people with solid tumors that have spread to soft tissues. The goal is to see if LRT shrinks tumors better and helps immune cells attack…

This study tests a program called MyCarePulse and ASCENT that helps cancer patients overcome food-related challenges. About 100 adults recently diagnosed with certain cancers will either get the program or standard care. Researchers will check if the program improves food securit…

This early-phase study tests whether fecal microbiota transplantation (FMT) can safely reduce severe diarrhea or colon inflammation caused by immune-checkpoint inhibitors in people with genitourinary and other cancers. About 40 participants will receive FMT and be monitored for s…

This study compares giving cancer treatment at home versus in a clinic for 27 adults with various cancers in the Florida Panhandle. The goal is to see if patients prefer home care and if it is safe. Participants will receive their usual cancer drugs either at home or in the clini…

This study is testing whether a virtual mind-body program called Integrative Medicine at Home (IM@Home) can help people with head and neck, thoracic, gynecologic, or other cancers feel less tired and have a better quality of life while receiving treatments like chemotherapy or ra…

This study aims to see if a statewide educational campaign can help people in Oregon spot the early signs of melanoma, a serious skin cancer. Researchers will compare awareness and early detection rates in Oregon with neighboring states that did not receive the campaign. Up to 75…

This study aims to see if a new predictive model can accurately tell which patients with melanoma and other skin cancers will respond to immunotherapy. Researchers will collect tumor tissue, blood, and stool samples from 1,000 participants and compare the model's predictions to a…

This study is following 2000 adults with newly diagnosed breast, colorectal, lung, melanoma, or lymphoma cancer who are receiving chemotherapy or immunotherapy. Researchers will track whether using cannabis or cannabinoids helps with symptoms like pain, nausea, or fatigue. No tre…

This study collects blood and tumor samples from 1,000 people with melanoma and healthy volunteers. Researchers want to learn more about what causes melanoma and how tumors behave. The samples will be stored for future research that could lead to better ways to diagnose or treat …

This study analyzes tumor samples from 12,000 cancer patients to find gene changes (mutations). The goal is to match each person with a clinical trial or therapy that targets their specific cancer type. Researchers will also build a database of mutations to improve future treatme…

This study is testing a new educational tool designed for people with melanoma who also have an autoimmune disease (like rheumatoid arthritis or Crohn's disease) and may receive immune checkpoint inhibitor drugs. Researchers want to see if the tool is easy to use and helpful for …

This study tests whether a mobile app called Vigilant can help monitor side effects in people with skin cancer or melanoma who are starting a type of immunotherapy. About 100 participants will use the app to report symptoms while at home. The goal is to see if remote monitoring i…

This study enrolls 7,000 people with various cancers who have had or will have treatment aimed at curing their disease. Researchers collect blood, tissue, urine, and saliva samples over time to look for tiny bits of cancer DNA that might remain after treatment. The goal is to lea…

This study screens up to 7,000 adults with cancers like melanoma, lung, or colorectal cancer to see if they qualify for experimental treatments developed by the National Cancer Institute's Surgery Branch. These treatments involve taking a patient's own immune cells, growing them …

This study tests a digital tool called mySmartSkin to help melanoma survivors do better skin self-exams. About 385 people who had melanoma will use the app and report how thoroughly they check their skin. The goal is to see if the app helps catch new or returning melanomas earlie…

This study collects blood and tissue samples from 2000 people—some with cancer, some without—to help researchers develop and improve blood tests that can detect many types of cancer early. Participants provide samples that are stored and later used to test new diagnostic methods.…

This study collects and stores tissue samples from 3,000 people with melanoma to learn about the biological changes that happen as the disease starts and grows. The goal is to use this information to help doctors and patients choose the best treatments. Participants must have a c…

This study monitors patients who have already received at least one dose of Replimune's experimental cancer therapy (RPx) for up to 5 years. The goal is to identify any delayed side effects or infections related to the treatment. No new drugs are given—participants simply provide…

This study tracks 270 women under 40 who have had melanoma surgery and are now taking newer drugs (immunotherapy or targeted therapy) to prevent the cancer from coming back. Researchers want to see if these treatments harm the ovaries by measuring a hormone called AMH before and …

This study is testing whether an artificial intelligence (AI) tool can help match people with advanced cancer to the right clinical trials. Researchers will enroll up to 50,000 participants to see if the AI improves trial enrollment rates and patient outcomes. The goal is to make…

This study looks at whether combining a special PET/CT scan with a blood test for tumor DNA can help doctors predict which patients with advanced melanoma will respond to immunotherapy. Researchers will compare changes in the scan and blood test results from before treatment to a…

This study tests whether urolithin A, a natural compound, can improve how the immune system responds to standard immunotherapy in people with solid tumors like lung cancer or melanoma. About 45 participants who have not had prior cancer treatment will receive either urolithin A o…

This study looks at whether watching a video before genetic testing helps people with certain cancers understand their hereditary risk better. About 1020 adults with breast, ovarian, pancreatic, prostate, colorectal, renal, melanoma, or sarcoma cancers will take part. Researchers…

This study looks at the genetic information inside tumor samples from children and teens with melanoma or related skin growths. Researchers want to learn what makes these rare cancers different from adult melanomas. The study does not test any new treatments, but it may help doct…

This study looks at how genes and environment affect melanoma risk in people with a personal or family history of the disease. Up to 3,000 participants will fill out questionnaires, give blood or cheek cell samples, and may have skin exams and biopsies. The goal is to find genes …

This study looks at how the COVID-19 pandemic impacted the well-being and quality of life of people with melanoma. Researchers are surveying over 1,100 participants about their experiences, stress, finances, and social life during the pandemic. The goal is to understand what help…

This study looks at whether giving young adults (ages 18-39) with cancer the choice of how to report their symptoms and quality of life leads to better data. About 400 participants will be randomly assigned to either pick their preferred reporting method or use a fixed one. The g…

This study tracks fertility changes in 80 people (women 18-37, men 18-45) receiving adjuvant therapy for high-risk melanoma. Researchers measure hormone levels in women and sperm quality in men before, right after, and one year after treatment. The goal is to understand how anti-…

This study collects blood and leftover tissue samples from 9,600 adults with different types of cancer, such as breast, lung, and pancreatic cancer. Researchers will use these samples to improve tests that look for tiny bits of cancer DNA in the blood, which may help detect if ca…

This study follows 350 adults with stage III-IV melanoma for two years after diagnosis to understand their quality of life and mental health. Researchers will also test whether a type of talk therapy called cognitive behavioral therapy (CBT) can help reduce cancer-related distres…

This study looks at how electrochemotherapy—a treatment that uses electric pulses to help chemotherapy drugs enter tumor cells—changes the environment around melanoma skin tumors. Researchers will collect tissue samples from 150 adults with melanoma before and after treatment to …

This study aims to collect blood samples (liquid biopsies) from 2,500 people with cancer or at high risk for cancer, along with their medical information. The samples will be stored and used by researchers to develop better ways to detect, monitor, and understand cancer over time…

This study looks at whether people with certain cancers prefer getting their immunotherapy (nivolumab or pembrolizumab) as a shot under the skin or as an IV drip. About 880 patients will try both methods and say which they like better. The goal is to understand patient preference…

This study is testing whether a blood test that looks for tumor DNA (ctDNA) can find cancer returning sooner than standard scans. Researchers will follow 100 people with various solid tumors to see if early detection leads to better treatment options. The goal is to improve how w…

This study looks at how a standard melanoma immunotherapy (anti-PD1) changes the appearance and biology of atypical moles in 30 people with stage IIB-IIIC melanoma. Participants must have at least two atypical moles and be already receiving this therapy as part of their care. The…

This study looks at how effective first-line immunotherapy is for people with metastatic melanoma in Slovenia. Researchers will track treatment response and safety, and analyze blood, stool, and body fluids to find markers that predict who benefits most. The goal is to improve pe…

This study is creating a large database of medical information and biological samples from adults with or at risk for many types of cancer, as well as healthy volunteers. The goal is to help researchers better understand what causes cancer, how it progresses, and how to improve p…